BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy

@article{Sloot2016BRAFIF,
  title={BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy},
  author={Sarah Sloot and Jonathan S. Zager and Ragini Reiney Kudchadkar and Jane L. Messina and Jacob J Benedict and Ricardo J. Gonzalez and Ronald C Deconti and Leslie M. Turner and Timothy W. McCardle and Keiran S. M. Smalley and Jeffrey S. Weber and Vernon K. Sondak and Geoffrey Thomas Gibney},
  journal={Melanoma Research},
  year={2016},
  volume={26},
  pages={83–87}
}
Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can be utilized as a neoadjuvant strategy. Data on patients with advanced locoregional BRAF V600E mutant melanoma treated with BRAF-targeted therapy at Moffitt Cancer Center were… 
Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma
TLDR
Patients with a pCR had significantly improved relapse‐free (RFS) and overall survival (OS) compared to patients with residual tumor, and neoadjuvant BRAF‐targeted therapy is associated with a high pCR rate in patients with stage III‐IV melanoma, which may correlate with improved RFS and OS.
Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
TLDR
Neoadjuvant BRAF inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.
18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients
TLDR
Baseline 18F-FDG PET or PET response in previous unresectable stage III melanoma patients seems not useful to predict pathologic response after neoadjuvant BRAF/MEK inhibitors treatment, however, PET/CT seems valuable in detecting recurrence early after R0 resection.
Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma
TLDR
Improvement in relapse-free survival has been noted and additional follow-up of patients receiving neoadjuvant treatment will be necessary to report on long-term outcomes, but more investigation is necessary to determine efficacious regimens with manageable toxicities.
18 F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
TLDR
PET response in previous unresectable stage III melanoma patients seems not useful to predict pathologic re- sponse after neoadjuvant BRAF / MEK inhibitors treatment, however, PET/ CT seems valuable in detecting recurrence early after R0 resection.
Intralesional and systemic immunotherapy for metastatic melanoma
TLDR
Treatment options for locally advanced and metastatic melanoma are expanding with new developments in immunotherapy and immune checkpoint inhibitors, and the utility of these novel therapies in the adjuvant setting is currently being explored.
Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy.
TLDR
The current evidence and on-going trials are compiled in order to provide a comprehensive review of the different options available and underway in regards to the treatment of metastatic melanoma.
Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy
TLDR
Patients undergoing treatment with ICI or targeted therapies can safely undergo surgery without substantially increased risk of serious intraoperative and postoperative complications.
Perioperative BRAF inhibitors in locally advanced stage III melanoma
TLDR
Targeted therapy takes advantage of the high incidence of BRAF mutations in melanomas, most notably the V600E mutation, to treat patients with stage III malignant melanoma.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
TLDR
A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
TLDR
Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
TLDR
Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
TLDR
Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
TLDR
The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
TLDR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
TLDR
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.
TLDR
This ongoing phase 1b/2 study is evaluating the combination of LGX818, a potent, selective BRAF inhibitor, and MEK162, a selective MEK1/2 inhibitor, in BRAFi-naive and -pretreated patients with BRAF-mutant tumors.
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
  • G. Shah, N. Socci, P. Chapman
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2010
TLDR
The response proportion to TMZ in the neoadjuvant setting was 16%, not different than in the metastatic setting, and Responses were seen even in tumors with a methylated MGMT promoter.
...
...